Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can High-Dose chemo make liver tumors operable?

NCT ID NCT00208260

Disease control Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether more intense chemotherapy combinations could shrink liver tumors in people with colorectal cancer that cannot be fully removed by surgery. 124 participants received either standard two-drug chemo or one of three stronger regimens. The goal was to see if the stronger treatments would make the tumors small enough for surgery, while also tracking side effects and survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
chemotherapy (FOLFIRI, FOLFOX, FOLFIRINOX)
What this could lead to
If successful, this could show that more intense chemotherapy helps shrink liver tumors enough to allow surgical removal, potentially improving survival.
What could go wrong
This is an older, completed trial with only 124 participants, so results may not apply broadly. Stronger chemo also raises the risk of severe side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

124 people

The number who actually took part.

Start date

Apr 2004

Finished

Aug 2007

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically proven adenocarcinoma of the colon or rectum without previous resection, or clinically asymptomatic (with or without stent) * Hepatic unresectable metastases R0: due to close vascular contact, or due to liver remaining mass less than 25 to 30 % of functional liver. * Not optimally resectable metastases * Extra-hepatic disease will be accepted in case of: asymptomatic primary tumour or tumor requiring no urgent surgery (in less than 3 months); three of less than three lung metastases (thoracic scan diameter less than 2 cm) and potentially respectable. * Synchronous and metachronous hepatic metastases * WHO performance status 0-1 * Adjuvant chemotherapy allowed, except oxaliplatin and irinotecan based combination. * No prior treatment of the liver metastases, whatever. * Life expectancy equal or more than 3 months Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemotherapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chemotherapy Colorectal cancer Liver metastases

Contacts and locations

Locations

  • CRLC Val d'Aurelle

    Montpellier, 34298, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.